Physician profile
Harendra Ipalawatte
NPI 1326788142
$820.48
in general payments reported to CMS, 2019-2025
12 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $95.37 · 2023: $261 · 2024: $145 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $164.64 | 2022-2023 | Jesduvroq, Benlysta |
| Novo Nordisk INC | $149.47 | 2025 | Ozempic |
| Chiesi USA, INC. | $146.96 | 2025 | Mycapssa |
| Astrazeneca Pharmaceuticals LP | $114.76 | 2024 | Airsupra |
| Aurinia Pharma U.S., INC. | $48.38 | 2023 | Lupkynis |
| Travere Therapeutics, INC. | $44.05 | 2023 | |
| Amgen INC. | $30.49 | 2024 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.79 | 2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $27.37 | 2023 | Jynarque |
| Btg International INC. | $24.90 | 2023 | |
| Viatris Specialty LLC | $22.73 | 2025 | Yupelri |
| Vapotherm INC | $17.94 | 2023 | Vapotherm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harendra Ipalawatte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.